Compare · ADMP vs NVO
ADMP vs NVO
Side-by-side comparison of Adamis Pharmaceuticals Corporation (ADMP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2096.0x ADMP ($87.4M).
- NVO has hit the wire 8 times in the past 4 weeks while ADMP has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for ADMP).
- Company
- Adamis Pharmaceuticals Corporation
- Novo Nordisk A/S
- Price
- $0.79+1.53%
- $41.01-4.51%
- Market cap
- $87.4M
- $183.15B
- 1M return
- -
- -10.44%
- 1Y return
- -
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ADMP
- Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form SC 13G/A filed by Adamis Pharmaceuticals Corporation (Amendment)
- Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by Adamis Pharmaceuticals Corporation
- Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Adamis Pharmaceuticals Corporation
- Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
- Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care